Dr. Ailani The last thing people with migraine need is more head pain, so MOH is essential to look out for. Ibuprofen is not the only medication with MOH risk (see chart below). It’s crucial to ...

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Fowler, 43, a therapist in Chicago, has now shifted her practice to supporting clients who live with chronic and ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

then ACP suggests clinicians use monotherapy with the antiseizure medication topiramate. Migraine is characterized by recurrent episodes of usually moderate-to-severe intensity headache lasting ...

In other recent news, Axsome Therapeutics, a biopharmaceutical company, announced that the FDA has approved SYMBRAVO®, a novel treatment for migraines in adults. The approval was based on results ...

The American College of Physicians (ACP) has developed new recommendations to prevent episodic migraines in nonpregnant adults in outpatient settings.